vs
Side-by-side financial comparison of Krispy Kreme, Inc. (DNUT) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $392.4M, roughly 1.8× Krispy Kreme, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs -7.1%, a 26.2% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs -2.9%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $27.9M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs -5.9%).
Krispy Kreme, Inc. is an American multinational doughnut company and coffeehouse chain. Krispy Kreme was founded by Vernon Rudolph (1915–1973), who bought a yeast-raised recipe from a New Orleans chef, rented a building in 1937 in what is now historic Old Salem in Winston-Salem, North Carolina, and began selling to local grocery stores. Steady growth preceded an ambitious expansion as a public company in the period 2000 to 2016, which ultimately proved unprofitable. In 2016, the company retur...
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
DNUT vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $392.4M | $708.5M |
| Net Profit | $-27.8M | $135.1M |
| Gross Margin | — | — |
| Operating Margin | -1.9% | 21.6% |
| Net Margin | -7.1% | 19.1% |
| Revenue YoY | -2.9% | 32.0% |
| Net Profit YoY | -23.8% | 15.5% |
| EPS (diluted) | $-0.18 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $392.4M | $708.5M | ||
| Q3 25 | $375.3M | $659.9M | ||
| Q2 25 | $379.8M | $603.3M | ||
| Q1 25 | $375.2M | $558.6M | ||
| Q4 24 | $404.0M | $536.6M | ||
| Q3 24 | $379.9M | $533.3M | ||
| Q2 24 | $438.8M | $528.1M | ||
| Q1 24 | $442.7M | $511.0M |
| Q4 25 | $-27.8M | $135.1M | ||
| Q3 25 | $-19.4M | $111.1M | ||
| Q2 25 | $-435.3M | $90.3M | ||
| Q1 25 | $-33.3M | $114.6M | ||
| Q4 24 | $-22.4M | $117.0M | ||
| Q3 24 | $39.6M | $96.4M | ||
| Q2 24 | $-5.5M | $88.4M | ||
| Q1 24 | $-8.5M | $102.6M |
| Q4 25 | -1.9% | 21.6% | ||
| Q3 25 | -1.9% | 21.5% | ||
| Q2 25 | -114.4% | 20.9% | ||
| Q1 25 | -5.4% | 20.3% | ||
| Q4 24 | -2.8% | 23.4% | ||
| Q3 24 | -4.2% | 21.1% | ||
| Q2 24 | 1.6% | 19.9% | ||
| Q1 24 | 2.7% | 20.4% |
| Q4 25 | -7.1% | 19.1% | ||
| Q3 25 | -5.2% | 16.8% | ||
| Q2 25 | -114.6% | 15.0% | ||
| Q1 25 | -8.9% | 20.5% | ||
| Q4 24 | -5.6% | 21.8% | ||
| Q3 24 | 10.4% | 18.1% | ||
| Q2 24 | -1.3% | 16.7% | ||
| Q1 24 | -1.9% | 20.1% |
| Q4 25 | $-0.18 | $4.65 | ||
| Q3 25 | $-0.11 | $3.86 | ||
| Q2 25 | $-2.55 | $3.10 | ||
| Q1 25 | $-0.20 | $3.67 | ||
| Q4 24 | $-0.13 | $3.67 | ||
| Q3 24 | $0.23 | $3.01 | ||
| Q2 24 | $-0.03 | $2.75 | ||
| Q1 24 | $-0.05 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $42.4M | $497.0M |
| Total DebtLower is stronger | $911.9M | — |
| Stockholders' EquityBook value | $650.1M | $459.1M |
| Total Assets | $2.6B | $2.0B |
| Debt / EquityLower = less leverage | 1.40× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $42.4M | $497.0M | ||
| Q3 25 | $30.7M | $285.4M | ||
| Q2 25 | $21.3M | $46.3M | ||
| Q1 25 | $18.7M | $441.4M | ||
| Q4 24 | $29.0M | $669.4M | ||
| Q3 24 | $25.4M | $656.9M | ||
| Q2 24 | $28.6M | $510.9M | ||
| Q1 24 | $33.1M | $407.0M |
| Q4 25 | $911.9M | — | ||
| Q3 25 | $906.2M | — | ||
| Q2 25 | $889.4M | — | ||
| Q1 25 | $935.0M | — | ||
| Q4 24 | $844.5M | — | ||
| Q3 24 | $804.6M | — | ||
| Q2 24 | $895.0M | — | ||
| Q1 24 | $881.8M | — |
| Q4 25 | $650.1M | $459.1M | ||
| Q3 25 | $670.3M | $293.6M | ||
| Q2 25 | $693.6M | $172.4M | ||
| Q1 25 | $1.1B | $593.6M | ||
| Q4 24 | $1.1B | $825.5M | ||
| Q3 24 | $1.2B | $881.4M | ||
| Q2 24 | $1.1B | $763.6M | ||
| Q1 24 | $1.2B | $671.5M |
| Q4 25 | $2.6B | $2.0B | ||
| Q3 25 | $2.6B | $1.8B | ||
| Q2 25 | $2.6B | $1.6B | ||
| Q1 25 | $3.1B | $1.9B | ||
| Q4 24 | $3.1B | $2.1B | ||
| Q3 24 | $3.1B | $2.1B | ||
| Q2 24 | $3.2B | $1.9B | ||
| Q1 24 | $3.2B | $1.8B |
| Q4 25 | 1.40× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.28× | — | ||
| Q1 25 | 0.85× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.79× | — | ||
| Q1 24 | 0.76× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.0M | $192.7M |
| Free Cash FlowOCF − Capex | $27.9M | $188.1M |
| FCF MarginFCF / Revenue | 7.1% | 26.6% |
| Capex IntensityCapex / Revenue | 4.4% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $-64.0M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.0M | $192.7M | ||
| Q3 25 | $42.3M | $246.2M | ||
| Q2 25 | $-32.5M | $148.5M | ||
| Q1 25 | $-20.8M | $125.8M | ||
| Q4 24 | $27.0M | $190.7M | ||
| Q3 24 | $3.3M | $149.1M | ||
| Q2 24 | $33.2M | $116.4M | ||
| Q1 24 | $-17.7M | $152.7M |
| Q4 25 | $27.9M | $188.1M | ||
| Q3 25 | $15.5M | $235.5M | ||
| Q2 25 | $-60.8M | $142.4M | ||
| Q1 25 | $-46.7M | $115.8M | ||
| Q4 24 | $-6.9M | $183.0M | ||
| Q3 24 | $-22.9M | $138.5M | ||
| Q2 24 | $1.6M | $103.5M | ||
| Q1 24 | $-46.8M | $147.2M |
| Q4 25 | 7.1% | 26.6% | ||
| Q3 25 | 4.1% | 35.7% | ||
| Q2 25 | -16.0% | 23.6% | ||
| Q1 25 | -12.5% | 20.7% | ||
| Q4 24 | -1.7% | 34.1% | ||
| Q3 24 | -6.0% | 26.0% | ||
| Q2 24 | 0.4% | 19.6% | ||
| Q1 24 | -10.6% | 28.8% |
| Q4 25 | 4.4% | 0.6% | ||
| Q3 25 | 7.1% | 1.6% | ||
| Q2 25 | 7.4% | 1.0% | ||
| Q1 25 | 6.9% | 1.8% | ||
| Q4 24 | 8.4% | 1.4% | ||
| Q3 24 | 6.9% | 2.0% | ||
| Q2 24 | 7.2% | 2.4% | ||
| Q1 24 | 6.6% | 1.1% |
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | 0.08× | 1.55× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | — | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DNUT
Segment breakdown not available.
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
